BridgeBio Pharma (BBIO) CEO reports RSU vesting and tax withholding share disposition
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma, Inc. Chief Executive Officer Neil Kumar reported routine equity compensation activity involving Restricted Stock Units (RSUs) and related tax withholding. On May 16, 2026, RSUs covering 71,215 shares of common stock vested and were converted into shares, as reflected by multiple M-code derivative exercises. A total of 36,236 shares of common stock were disposed of under code F at $66.13 per share to satisfy tax obligations, not as an open-market sale, leaving 269,430 common shares held directly. Kumar also has indirect interests in 4,358,447 common shares held by the Kumar Haldea Revocable Trust and 555,686 shares held by the Kumar Haldea Family Irrevocable Trust, with beneficial ownership of these trust holdings disclaimed except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Routine RSU vesting with tax withholding; no open-market buying or selling.
Neil Kumar, CEO of BridgeBio Pharma, Inc., reported vesting and settlement of RSU awards converting 71,215 RSUs into common shares. These M-code entries are standard compensation-related derivative exercises rather than discretionary market purchases.
The filing also shows an F-code disposition of 36,236 shares at $66.13 per share to cover tax obligations tied to the RSU vesting. This share withholding is a non-market event and does not represent an open-market sale. Following these transactions, Kumar holds 269,430 shares directly and has indirect interests in trust-held shares, with beneficial ownership disclaimed except for any pecuniary interest.
Insider Trade Summary
71,215 shares exercised/converted
Mixed
11 txns
Insider
Kumar Neil
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 33,544 | $0.00 | -- |
| Exercise | Restricted Stock Units | 19,599 | $0.00 | -- |
| Exercise | Restricted Stock Units | 11,553 | $0.00 | -- |
| Exercise | Restricted Stock Units | 6,519 | $0.00 | -- |
| Exercise | Common Stock | 33,544 | $0.00 | -- |
| Exercise | Common Stock | 19,599 | $0.00 | -- |
| Exercise | Common Stock | 11,553 | $0.00 | -- |
| Exercise | Common Stock | 6,519 | $0.00 | -- |
| Tax Withholding | Common Stock | 36,236 | $66.13 | $2.40M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 100,632 shares (Direct, null);
Common Stock — 267,995 shares (Direct, null);
Common Stock — 555,686 shares (Indirect, By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.)
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,215 shares of Common Stock underlying the Reporting Person's RSUs. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. The RSUs will vest with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.
Key Figures
RSUs vested and converted: 71,215 shares
Tax-withholding shares: 36,236 shares
Tax-withholding price: $66.13 per share
+3 more
6 metrics
RSUs vested and converted
71,215 shares
Common stock underlying RSUs vesting as of May 16, 2026
Tax-withholding shares
36,236 shares
Shares withheld to satisfy tax obligations on RSU vesting
Tax-withholding price
$66.13 per share
Value used for 36,236-share F-code disposition
Direct common shares after transactions
269,430 shares
Neil Kumar’s direct BridgeBio common stock holding post-Form 4
Revocable trust holding
4,358,447 shares
Common stock held by Kumar Haldea Revocable Trust, indirect interest
Family irrevocable trust holding
555,686 shares
Common stock held by Kumar Haldea Family Irrevocable Trust, indirect interest
Key Terms
Restricted Stock Unit ("RSU"), tax-withholding disposition, beneficial ownership, Section 16, +1 more
5 terms
Restricted Stock Unit ("RSU") financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."
tax-withholding disposition financial
"Represents number of shares ... withheld to satisfy the Reporting Person's tax obligation in connection with the vesting ..."
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
beneficial ownership regulatory
"The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any..."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What did BridgeBio Pharma (BBIO) CEO Neil Kumar report in this Form 4?
Neil Kumar reported routine equity compensation activity. RSUs covering 71,215 shares vested into common stock, and 36,236 shares were withheld at $66.13 per share to satisfy tax obligations, leaving 269,430 shares held directly after the transactions.
Were any of Neil Kumar’s BridgeBio Pharma (BBIO) transactions open-market buys or sells?
No open-market buys or sells were reported. The filing shows M-code exercises of RSUs into common stock and an F-code disposition of 36,236 shares strictly to cover tax liabilities related to the vesting of 71,215 RSU-based shares.
What do the RSU vesting footnotes in Neil Kumar’s BridgeBio Pharma (BBIO) Form 4 explain?
The footnotes explain that each RSU equals one common share. Several RSU grants vest in 1/16 increments on May 16 of 2023, 2024, 2025, and 2026, then quarterly, subject to Kumar’s continued service, and the RSUs have no expiration date.